Investigational drug · Phase 3
BR1018A-1
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Essential Hypertension, Primary Hypercholesterolemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "BR1018A-1"
First trial start
2024
Apr 17, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BR1018A-1", any sponsor or status.
Conditions studied
As listed on its trial records.
- Essential Hypertension
- Primary Hypercholesterolemia
Approved drugs for the same conditions: High blood pressure (hypertension) · High cholesterol · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "BR1018A-1" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018CPivotal-lookingCompleted
Boryung Pharmaceutical Co., LtdIndustry
NCT06165250 · 151 participants · Start Apr 17, 2024 · Primary completion Nov 11, 2025
Drug: BR1018A; BR1018A-1 and 4 more · For: Essential Hypertension; Primary Hypercholesterolemia
Sites: Daegu, South Korea; Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Essential Hypertension
- DWC202314Phase 32 trials
Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension
- DWC202314PPhase 32 trials
Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension
- Experimental: SacubitrilPhase 32 trials
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Essential Hypertension
- AD-227APhase 31 trial
Addpharma Inc. · Essential Hypertension
- AD-227BPhase 31 trial
Addpharma Inc. · Essential Hypertension
- AD-227CPhase 31 trial
Addpharma Inc. · Essential Hypertension
- ATB-1011Phase 31 trial
Autotelicbio · Essential Hypertension, Diabetes Mellitus, Type 2
- ATB-1012Phase 31 trial
Autotelicbio · Essential Hypertension, Diabetes Mellitus, Type 2
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.